— Know what they know.
Not Investment Advice

ICCC

ImmuCell Corporation
1W: -4.5% 1M: -8.8% 3M: -0.2% YTD: +2.7% 1Y: +26.1% 3Y: +16.9% 5Y: -43.5%
$6.07
-0.08 (-1.30%)
After Hours: $6.63 (+0.56, +9.23%)
NASDAQ · Healthcare · Biotechnology · $54.9M · Alpha Radar Neutral · Power 39
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$54.9M
52W Range4.52-7.6
Volume24,432
Avg Volume24,454
Beta0.30
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEOF. Olivier Te Boekhorst
Employees69
SectorHealthcare
IndustryBiotechnology
IPO Date1987-05-05
56 Evergreen Drive
Portland, ME 04103
US
207 878 2770
About ImmuCell Corporation

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Recent Insider Trades

NameTypeSharesPriceDate
te Boekhorst Paul Fr 25,329 $5.90 2028-09-16
Fiori Timothy C A-Award 120,000 $6.26 2026-01-27
Brockmann Bobbi Jo A-Award 100,000 $6.26 2026-01-27
te Boekhorst Paul Fr A-Award 110,000 $6.26 2026-01-27
te Boekhorst Paul Fr P-Purchase 2,432 $5.50 2025-12-04

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms